HPLC-MS/MS method to measure trabectedin in tumors: Preliminary PK study in a mesothelioma xenograft model

Bioanalysis

Volumn 7, Issue 15, 2015, Pages 1831-1842

  Ceriani, Laura ^a   Ferrari, Mariella ^a   Zangarini, Monique ^a   Licandro, Simonetta Andrea ^a   Bello, Ezia ^a   Frapolli, Roberta ^a   Falcetta, Francesca ^a   D'Incalci, Maurizio ^a   Libener, Roberta ^b   Grosso, Federica ^b   Aviles, Pablo ^c   Zucchetti, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SS Antonio e Biagio General Hospital   (Italy)

^c PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIVER; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; VALIDATION STUDY; ANIMAL; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; MESOTHELIOMA; METABOLISM; NUDE MOUSE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIOXOLES; FEMALE; HUMANS; MESOTHELIOMA; MICE; MICE, NUDE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940182467     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.117     Document Type: Article

References (14)

1. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9(8), 2157-2163 (2010).
2. Grosso F, Sanfilippo R, Virdis E et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann. Oncol. 20(8), 1439-1444 (2009).
3. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28(19), 3107-3114 (2010).
4. Poveda A, Ray-Coquard I, Romero I et al. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat. Rev. 40(3), 366-375 (2014).
5. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 13(7), 1600-1608 (1995).
6. Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 26(3), 322-337 (2009).
7. Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249-262 (2013).
8. Rosing H, Hillebrand MJ, Jimeno JM et al. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 33, 1134-1140 (1998).
9. Stokvis E, Rosing H, López-Lázaro L et al. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. J. Mass Spectrom. 39 431-436 (2004).
10. Zangarini M, Ceriani L, Sala F et al. Quantification of trabectedin in human plasma: Validation of a highperformance liquid chromatography-mass spectrometry method and its application in a clinical pharmacokinetic study. J. Pharm. Biomed. Anal. 95, 107-112 (2014).
11. Beumer JH, Franke NE, Tolboom R et al. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Invest. New Drugs 28(2), 145-155 (2010).
12. European Medicines Agency. Guideline on bioanalytical method validation. Committee for Medicinal Products for Human Use (CHMP), London, UK (2011). www. ema. europa. eu
13. Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. Center for Drug Evaluation and Research (CDER) (2001). www. fda. gov
14. Uboldi S, Bernasconi S, Romano M et al. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int. J. Cancer 131(1), 59-69 (2012).